. 2023 Jun;51(6):700–717. doi: 10.1124/dmd.122.001010

TABLE 2.

Binding affinities of xenobiotic ligands with different FABPs

	Range of Reported K_i and K_d Values (µM)
Ligand	FABP1		FABP2		FABP3	FABP4	FABP5	FABP7
Acifluorfen			4.2-8.9
ANS	1.1-6.0 1.1^a	12^b	3.0-31^c		0.6	0.03-32	0.07-1.3
Aspirin	348^a	3780^b	300-460
Atenolol	717		NB^c
Benzafibrate	NB^a	44.4^b	26-100^c		NB	12	NB
Benzilic acid			110.8-200^c
Benzyl salicylate			NB
Bifenox			NB
BMS309403							0.9
CBD	4.0				1.7		1.9	1.5
Ciprofibrate			24-72^c
Clofibrate	6.9
Clofibric acid			17.7-110^c		NB	17	NB
Cortexolone			1600-1900
DAUDA	0.4-1.4		0.3-0.7^c
Dexamethasone	22.1^a	41.3^b	1100-1200
Diazepam	0.5^a	115^b	1980-2200 NB^c		NB	NB	325
Diclofenac	3.2^a	35^b	86.3-520^c
Dilitiazem			NB^c
Fenbofibric acid	1-1.6, 0.3^a	27.5^b	1-6.1^c		33	24	3.3
Fenofibrate	2.9 0.02^a	0.4^b	0.8 NB^c
Fenoprofen			14-64^c
Flufenamic acid			3.7-15.5
(R/S) Flurbiprofen	1.2^a	222^b	20-70
Gemfibrozil	1.9^a	179^b	110.5-121.3^c		NB	3.8	6.1
GW7647	0.3-0.6		1.3^c		25	7.6	0.7-8.9
(R/S) Ibuprofen	47.6^a	448^b	32.2-263^c		325	2.6	138
3-indolacetic acid			93-200
Indole-3-butyric acid			72-170
Indoprofen	1.27^a	161^b	129-520.1
Jasmonic acid			140-350
Ketoprofen			24-82.4^c
Ketorolac	11.6^a	119^b	9.4-2300^c
Lorazepam	12.9^a	140^b	2100-2500
Meclofenamic acid	0.4^a	0.3^b	8.9-21^c
Mefenamic acid			63-110		5.8	1.1	4.3
Mepronil			NB
Midazolam	7.9		12
Nabumetone			NB^c
Nadolol	2310
Nalidixic acid			NB
2-naphthoxyacetic acid			7.2-14
(S)-(-)-Naproxen	0.06^a^,^c	2.8^b,^c	56-180
Nitrazepam			1200-2300^c		28	36	20
Perfluorononanoic acid	1.3-3.1^c
Perfluorooctanoic acid	2.4-6.5^c
Phenytoin			0.2^a NB	4.7^b
Pioglitazone					33	NB	11
Prednisolone	2.7^a	101^b	95-113
Progesterone	0.03		20-32
Propanolol	NB		NB
Pyrilamine			NB
Rosiglitazone	2.8				NB	NB	28.8
Sulfinpyrazone	0.1^c	8.2^c
THC	0.1-2.9				2.0		3.1	1
11-COOH-THC	11.2 NB
11-COOH-THC-glucuronide	NB
11-OH-THC	5-7.2 NB
Tolfenamic acid			2.8-8.2^c		1.9	0.1	2.9
Tolmetin			1300-2200
Torsemide	0.2^c	12.3^c	0.8
Troglitazone	1.7				11	0.02-16	1
Valproate			240-470
Verapamil			NB

^aAffinity for first, high affinity binding site.

^bAffinity for second, low affinity binding site respectively, determined in the same study as in ^a.

^cIncludes studies where binding affinities were determined by SPR, ITC, or thermal shift with SYPRO Orange.

CBD, cannabidiol; DAUDA, 11-(dansylamino)undecanoic acid; THC, Δ⁹-tetrahydrocannabinol.

NB indicates that binding was tested but no binding was observed in at least one study.

References Thumser et al., 1996; Veerkamp et al., 1999; Velkov et al., 2005, 2007, 2009; Gillilan et al., 2007; Chuang et al., 2008; Rowland et al., 2009, 2015; Trevaskis et al., 2011; Kaczocha et al., 2012; Velkov, 2013; Patil et al., 2014; Yu et al., 2014; Elmes et al., 2015, 2019; Lee et al., 2015; Sheng et al., 2016; Huang et al., 2018.